CERE
Cerevel Therapeutics Holdings, Inc. Common StockCERE
CERE
Delisted
CERE was delisted on the 31st of July, 2024.
About: Cerevel Therapeutics Holdings Inc is dedicated to unraveling the mysteries of the brain to treat neuroscience diseases. The company is tackling neuroscience diseases with a differentiated approach that combines expertise in neurocircuitry with a focus on receptor selectivity. It has a diversified pipeline comprising five clinical-stage investigational therapies and several preclinical compounds with the potential to treat a range of neuroscience diseases, including schizophrenia, epilepsy, Parkinson's disease and substance use disorder. Cerevel Therapeutics is advancing its current research and development programs while exploring new modalities through internal research efforts, external collaborations or potential acquisitions.
Employees: 355
Financial journalist opinion
Neutral
Accesswire
13 hours ago
ROSEN, A LONGSTANDING FIRM, Encourages Cerevel Therapeutics Holdings, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - CERE
NEW YORK CITY, NY / ACCESS Newswire / May 13, 2025 / WHY: Rosen Law Firm, a global investor rights law firm, reminds persons or entities that (1) sold or otherwise disposed of the publicly-traded common stock of Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE) during the period from October 11, 2023 through August 1, 2024, inclusive (the "Class Period"); (2) held shares of Cerevel as of the January 8, 2024 record date and were entitled to vote on the merger of Cerevel and AbbVie Inc.; and/or (3) sold shares of Cerevel stock contemporaneously with Bain Capital's purchase of shares on or about October 16, 2023, of the important June 3, 2025 lead plaintiff deadline. SO WHAT: If you sold and/or held Cerevel common stock you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
Neutral
Accesswire
1 day ago
CERE INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Cerevel Therapeutics Holdings, Inc. Investors with Losses Have Opportunity to Lead Class Action Lawsuit!
NEW YORK CITY, NY / ACCESS Newswire / May 13, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Cerevel Therapeutics Holdings, Inc. ("Cerevel" or "the Company") (NASDAQ:CERE), Bain Capital Investors, LLC ("Bain") and Pfizer, Inc. ("Pfizer"). Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that: (a) sold or otherwise disposed of the publicly-traded common stock of Cerevel during the period from October 11, 2023 through August 1, 2024, inclusive, and thus were damaged by defendants' violations of Section 10(b) of the Securities Exchange Act of 1934 ("Exchange Act"); (b) held shares of Cerevel as of January 8, 2024 (the "Record Date") and were entitled to vote on the merger of Cerevel and AbbVie Inc. ("AbbVie") and thus were damaged by defendants' violations of Section 14(a) of the Exchange Act; and/or (c) sold shares of Cerevel stock contemporaneously with Bain's purchase of shares on or about October 16, 2023 and thus were damaged by Bain's violations of Section 20A of the Exchange Act.
Neutral
Accesswire
1 day ago
SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Cerevel Therapeutics
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Cerevel To Contact Him Directly To Discuss Their Options NEW YORK CITY, NY / ACCESS Newswire / May 12, 2025 / A class action was filed against against Cerevel Therapeutics Holdings, Inc. ("Cerevel" or the "Company"), Bain Capital Investors, LLC ("Bain") and Pfizer, Inc. ("Pfizer") on behalf of investors that (a) sold or otherwise disposed of the publicly-traded common stock of Cerevel during the period from October 11, 2023 through August 1, 2024, inclusive, and thus were damaged by defendants' violations of Section 10(b) of the Securities Exchange Act of 1934 ("Exchange Act"); (b) held shares of Cerevel as of January 8, 2024 (the "Record Date") and were entitled to vote on the merger of Cerevel and AbbVie Inc. ("AbbVie") and thus were damaged by defendants' violations of Section 14(a) of the Exchange Act; and/or (c) sold shares of Cerevel stock contemporaneously with Bain's purchase of shares on or about October 16, 2023 and thus were damaged by Bain's violations of Section 20A of the Exchange Act. If you would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext.
Neutral
Accesswire
1 day ago
ROSEN, LEADING INVESTOR COUNSEL, Encourages Cerevel Therapeutics Holdings, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - CERE
NEW YORK CITY, NY / ACCESS Newswire / May 12, 2025 / WHY: New York, N.Y., May 12, 2025.
Neutral
PRNewsWire
1 day ago
CERE Investors Have Opportunity to Lead Cerevel Therapeutics Holdings, Inc. Securities Fraud Lawsuit with the Schall Law Firm
LOS ANGELES , May 12, 2025 /PRNewswire/ -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Cerevel Therapeutics Holdings, Inc. ("Cerevel" or "the Company") (NASDAQ: CERE) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's shares between October 11, 2023 and August 1, 2024, inclusive (the "Class Period"); and/or held shares of Cerevel as of the January 8, 2024 record date and were entitled to vote on the merger of Cerevel and AbbVie Inc.; and/or sold shares of Cerevel stock contemporaneously with Bain Capital Investors, LLC's purchase of shares on or about October 16, 2023, are encouraged to contact the firm before June 3, 2025.
Neutral
Accesswire
2 days ago
CERE SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Cerevel Therapeutics Holdings, Inc. Stockholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
NEW YORK CITY, NY / ACCESS Newswire / May 12, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Cerevel Therapeutics Holdings, Inc. ("Cerevel" or "the Company") (NASDAQ:CERE), Bain Capital Investors, LLC ("Bain") and Pfizer, Inc. ("Pfizer"). Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that: (a) sold or otherwise disposed of the publicly-traded common stock of Cerevel during the period from October 11, 2023 through August 1, 2024, inclusive, and thus were damaged by defendants' violations of Section 10(b) of the Securities Exchange Act of 1934 ("Exchange Act"); (b) held shares of Cerevel as of January 8, 2024 (the "Record Date") and were entitled to vote on the merger of Cerevel and AbbVie Inc. ("AbbVie") and thus were damaged by defendants' violations of Section 14(a) of the Exchange Act; and/or (c) sold shares of Cerevel stock contemporaneously with Bain's purchase of shares on or about October 16, 2023 and thus were damaged by Bain's violations of Section 20A of the Exchange Act.
Neutral
Accesswire
2 days ago
ROSEN, A GLOBAL INVESTOR RIGHTS LAW FIRM, Encourages Cerevel Therapeutics Holdings, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - CERE
NEW YORK CITY, NY / ACCESS Newswire / May 11, 2025 / WHY: Rosen Law Firm, a global investor rights law firm, reminds persons or entities that (1) sold or otherwise disposed of the publicly-traded common stock of Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE) during the period from October 11, 2023 through August 1, 2024, inclusive (the "Class Period"); (2) held shares of Cerevel as of the January 8, 2024 record date and were entitled to vote on the merger of Cerevel and AbbVie Inc.; and/or (3) sold shares of Cerevel stock contemporaneously with Bain Capital's purchase of shares on or about October 16, 2023, of the important June 3, 2025 lead plaintiff deadline. SO WHAT:If you sold and/or held Cerevel common stock you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
Neutral
GlobeNewsWire
2 days ago
Faruqi & Faruqi Reminds Cerevel Therapeutics Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of June 3, 2025 - CERE
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Cerevel To Contact Him Directly To Discuss Their Options
Neutral
Accesswire
3 days ago
CERE SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Cerevel Therapeutics Holdings, Inc. Shareholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
NEW YORK CITY, NY / ACCESS Newswire / May 11, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Cerevel Therapeutics Holdings, Inc. ("Cerevel" or "the Company") (NASDAQ:CERE), Bain Capital Investors, LLC ("Bain") and Pfizer, Inc. ("Pfizer"). Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that: (a) sold or otherwise disposed of the publicly-traded common stock of Cerevel during the period from October 11, 2023 through August 1, 2024, inclusive, and thus were damaged by defendants' violations of Section 10(b) of the Securities Exchange Act of 1934 ("Exchange Act"); (b) held shares of Cerevel as of January 8, 2024 (the "Record Date") and were entitled to vote on the merger of Cerevel and AbbVie Inc. ("AbbVie") and thus were damaged by defendants' violations of Section 14(a) of the Exchange Act; and/or (c) sold shares of Cerevel stock contemporaneously with Bain's purchase of shares on or about October 16, 2023 and thus were damaged by Bain's violations of Section 20A of the Exchange Act.
Neutral
PRNewsWire
3 days ago
CERE Investors Have Opportunity to Lead Cerevel Therapeutics Holdings, Inc. Securities Fraud Lawsuit
NEW YORK , May 10, 2025 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds all persons or entities that: (1) sold or otherwise disposed of the publicly-traded common stock of Cerevel Therapeutics Holdings, Inc. (NASDAQ: CERE) during the period from October 11, 2023 through August 1, 2024, inclusive (the "Class Period"); (2) held shares of Cerevel as of the January 8, 2024 record date and were entitled to vote on the merger of Cerevel and AbbVie Inc.; and/or (3) sold shares of Cerevel stock contemporaneously with Bain Capital's purchase of shares on or about October 16, 2023, of the important June 3, 2025 lead plaintiff deadline. So what: If you sold and/or held Cerevel common stock you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
Charts implemented using Lightweight Charts™